107 related articles for article (PubMed ID: 1965030)
21. Binding and degradation of vasoactive intestinal peptide in prolactin-producing cultured rat pituitary tumour cells (GH4C1).
Bjøro T; Wiik P; Opstad PK; Gautvik KM; Haug E
Acta Physiol Scand; 1987 Aug; 130(4):609-18. PubMed ID: 2820199
[TBL] [Abstract][Full Text] [Related]
22. Distribution of vasoactive intestinal polypeptide (VIP) binding in circular muscle and characterization of VIP binding in canine small intestinal mucosa.
Mao YK; Barnett W; Coy DH; Tougas G; Daniel EE
J Pharmacol Exp Ther; 1991 Sep; 258(3):986-91. PubMed ID: 1653848
[TBL] [Abstract][Full Text] [Related]
23. PACAP and VIP receptors in rat liver membranes.
Robberecht P; Gourlet P; Cauvin A; Buscail L; De Neef P; Arimura A; Christophe J
Am J Physiol; 1991 Jan; 260(1 Pt 1):G97-102. PubMed ID: 1846275
[TBL] [Abstract][Full Text] [Related]
24. Vasoactive intestinal polypeptide receptors in rat cerebral vessels: an autoradiographic study.
Amenta F; Cavalotti C; De Michele M; De Vincentis G; Rossodivita A; Rossodivita I
J Auton Pharmacol; 1991 Oct; 11(5):285-93. PubMed ID: 1660895
[TBL] [Abstract][Full Text] [Related]
25. Characterization of binding sites for VIP-related peptides and activation of adenylate cyclase in developing pancreas.
Le Meuth V; Farjaudon N; Bawab W; Chastre E; Rosselin G; Guilloteau P; Gespach C
Am J Physiol; 1991 Feb; 260(2 Pt 1):G265-74. PubMed ID: 1847591
[TBL] [Abstract][Full Text] [Related]
26. Vasoactive intestinal peptide in cirrhotic rats: hemodynamic effects and mesenteric arterial receptor characteristics.
Lee SS; Huang M; Ma Z; Rorstad O
Hepatology; 1996 May; 23(5):1174-80. PubMed ID: 8621151
[TBL] [Abstract][Full Text] [Related]
27. Receptors for vasoactive intestinal peptide (VIP) on human mononuclear leucocytes are upregulated during prolonged strain and energy deficiency.
Wiik P; Opstad PK; Knardahl S; Bøyum A
Peptides; 1988; 9(1):181-6. PubMed ID: 2834700
[TBL] [Abstract][Full Text] [Related]
28. Receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in turkey cerebral cortex: characterization by [125I]-VIP binding and effects on cyclic AMP synthesis.
Zawilska JB; Niewiadomski P; Nowak JZ
Gen Comp Endocrinol; 2004 Jun; 137(2):187-95. PubMed ID: 15158130
[TBL] [Abstract][Full Text] [Related]
29. Effects of GTP analogs and dithiothreitol on the binding properties of the vascular vasoactive intestinal peptide receptor.
Huang M; Rorstad OP
Can J Physiol Pharmacol; 1989 Aug; 67(8):851-6. PubMed ID: 2557141
[TBL] [Abstract][Full Text] [Related]
30. Distribution of vasoactive intestinal polypeptide binding sites in guinea pig genital tissues.
Inyama CO; Wharton J; Davis CJ; Jackson RH; Bloom SR; Polak JM
Neurosci Lett; 1987 Oct; 81(1-2):111-6. PubMed ID: 2827063
[TBL] [Abstract][Full Text] [Related]
31. Molecular characteristics and peptide specificity of vasoactive intestinal peptide receptors from rat cerebral cortex.
Couvineau A; Gammeltoft S; Laburthe M
J Neurochem; 1986 Nov; 47(5):1469-75. PubMed ID: 3020175
[TBL] [Abstract][Full Text] [Related]
32. Characterization of vasoactive intestinal peptide (VIP) receptors in mammalian lung.
Dickinson KE; Schachter M; Miles CM; Coy DH; Sever PS
Peptides; 1986; 7(5):791-800. PubMed ID: 3025822
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the vasoactive intestinal peptide receptor in rat submandibular gland: radioligand binding assay in membrane preparations.
Turner JT; Bylund DB
J Pharmacol Exp Ther; 1987 Sep; 242(3):873-81. PubMed ID: 2821229
[TBL] [Abstract][Full Text] [Related]
34. Characterization of vasoactive intestinal peptide receptors in rat seminal vesicle.
Guijarro LG; Rodriguez-Pena MS; Prieto JC
Am J Physiol; 1991 Feb; 260(2 Pt 1):E286-91. PubMed ID: 1847588
[TBL] [Abstract][Full Text] [Related]
35. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 1. Molecular characterization of the binding site.
Luis J; Martin JM; el Battari A; Reynier M; Marvaldi J; Pichon J
Eur J Biochem; 1989 Mar; 180(2):429-33. PubMed ID: 2538330
[TBL] [Abstract][Full Text] [Related]
36. Interaction of vasoactive intestinal peptide (VIP) and N-terminally modified VIP analogs with rat pancreatic, hepatic and pituitary membranes.
Robberecht P; Coy DH; De Neef P; Camus JC; Cauvin A; Waelbroeck M; Christophe J
Eur J Biochem; 1986 Aug; 159(1):45-9. PubMed ID: 3017717
[TBL] [Abstract][Full Text] [Related]
37. Characterization of a high-affinity galanin receptor in the rat anterior pituitary: absence of biological effect and reduced membrane binding of the antagonist M15 differentiate it from the brain/gut receptor.
Wynick D; Smith DM; Ghatei M; Akinsanya K; Bhogal R; Purkiss P; Byfield P; Yanaihara N; Bloom SR
Proc Natl Acad Sci U S A; 1993 May; 90(9):4231-5. PubMed ID: 7683428
[TBL] [Abstract][Full Text] [Related]
38. Characterization and solubilization of vasoactive intestinal peptide receptors from rat lung membranes.
Provow S; Veliçelebi G
Endocrinology; 1987 Jun; 120(6):2442-52. PubMed ID: 3032591
[TBL] [Abstract][Full Text] [Related]
39. Vasoactive intestinal peptide and intraocular pressure: adenylate cyclase activation and binding sites for vasoactive intestinal peptide in membranes of ocular ciliary processes.
Mittag TW; Tormay A; Podos SM
J Pharmacol Exp Ther; 1987 Apr; 241(1):230-5. PubMed ID: 3033201
[TBL] [Abstract][Full Text] [Related]
40. Pharmacology and molecular identification of vasoactive intestinal peptide (VIP) receptors in normal and cancerous gastric mucosa in man.
Gespach C; Bawab W; Chastre E; Emami S; Yanaihara N; Rosselin G
Biochem Biophys Res Commun; 1988 Mar; 151(2):939-47. PubMed ID: 2831906
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
